Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Risk & Volatility
Achilles Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Achilles Therapeutics and MiNK Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Achilles Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
| MiNK Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Earnings & Valuation
This table compares Achilles Therapeutics and MiNK Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Achilles Therapeutics | N/A | N/A | -$69.67 million | ($1.65) | -0.84 |
| MiNK Therapeutics | N/A | N/A | -$22.46 million | ($3.90) | -2.37 |
MiNK Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Achilles Therapeutics and MiNK Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Achilles Therapeutics | N/A | -54.45% | -47.68% |
| MiNK Therapeutics | N/A | N/A | -189.14% |
Insider & Institutional Ownership
56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by company insiders. Comparatively, 20.6% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
MiNK Therapeutics beats Achilles Therapeutics on 6 of the 11 factors compared between the two stocks.
About Achilles Therapeutics
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
About MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
